Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting


Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 12?15, 2021 in New Orleans, Louisiana.

Key Glaucoma Presentations:

Key Glaucoma Courses:

Key Corneal Health Presentations:

Key Corneal Health Courses:

Abstracts and full session details can be found at www.aao.org/annual-meeting.

Glaukos will also be exhibiting on the showroom floor throughout AAO at booth #4015.

The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry. All educational content of the AAO Annual Meeting is planned by its program committee, and AAO does not endorse, promote, approve, or recommend the use of any products, devices or services.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in the presentations at the AAO meeting. These and other risks, uncertainties and factors related to Glaukos and our business are described in detail under the caption "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which was filed with the Securities and Exchange Commission (SEC) on November 8, 2021. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.


These press releases may also interest you

at 23:52
The newly released Net Zero Series has a high-power output of 210kW, with the capacity to charge multiple vehicles in less than 30 minutes. Equipped with an industrial socket for easy installation, the integrated BYD liquid-cooled battery packs can...

at 23:35
ITC Limited, one of India's leading marketers in the fast-moving consumer good business, is transforming its supply chain. The company has invested in two large, automated distribution centers to support its growth ambitions in the coming years....

at 23:27
Tech Soft 3D, the leading provider of engineering software development toolkits, today announces that Visual Components has integrated HOOPS toolkits to power their manufacturing facility planning and simulation platform. For more than 20 years,...

at 23:20
Collabtic has grown significantly since it's humble beginnings in 2017. Collabtic has become a business-critical platform for service organizations increasing service productivity and...

at 23:00
Klaytn will be establishing an Open Permissioned Blockchain (OPB), the Chongqing Chain, on the Blockchain-based Service Network (BSN)The BSN is a multi-chain infrastructure network that currently supports 28 blockchain frameworks, 19 portals, and...

at 22:45
Allied Universal®, the leading global security and facility services company, today announced the acquisition of American Security, a top security provider in the Southeast region of the United States....



News published on 11 november 2021 at 07:05 and distributed by: